More on PHVS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (9.2 Score)

Upcoming Events

- Earnings (8/19/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Pharvaris (NQ:PHVS)
Delayed: 33.97 -0.2 (0.59%)
Prev. Close $34.17  
Open$34.17 
52 Wk High$ 
52 Wk Low$ 
Day High$34.85 
Day Low$33.84 
P/E N/A  
EPS$ 
Volume213,201 

Friends, Peers and Foes (?): ABBV, ACAD, ARWR, ASND, BCRX (more...)

Jul 22, 2026 06:50 AM Pharvaris publishes review on bradykinin B2 receptor as therapy target
Jul 22, 2026 06:50 AM Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Jul 22, 2026 06:50 AM Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Jul 15, 2026 01:08 PM Form 4 Pharvaris N.V. For: Jul 13 Filed by: Modig Berndt
Jul 15, 2026 05:11 AM Wells Fargo Starts Pharvaris B.V. (PHVS) at Overweight
Jul 14, 2026 03:47 PM Form 4 Pharvaris N.V. For: Jul 11 Filed by: Lu Peng
Jul 13, 2026 04:39 PM Form 144 Pharvaris N.V. Filed by: Modig Berndt
Jul 6, 2026 06:50 AM FDA accepts Pharvaris NDA for oral HAE attack treatment deucrictibant
Jul 6, 2026 06:50 AM Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
Jul 1, 2026 07:06 PM Form 4 Pharvaris N.V. For: Jun 29 Filed by: Schikan Johannes Gerardus Christiaan Petrus
View All Articles

Entities mentioned with PHVS

View All Entities